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Neuroplasticity, defined as the changing of the structure, function, 
and organization of neurons, has emerged as an interesting target 
for the development of new and effective treatments for multiple 
neurodegenerative diseases. 
In this study, we have applied our proprietary computational 
platform, Symmetry®, t o assess more than 30 molecular and cel-
lular targets involved in neuroplasticity and start designing potential 
small-molecule modulators. 
This chemoinformatics technology is applied on top of large 
amounts of factual data and is able t o characterize multiple mo-
lecular mechanisms of action and other important pharmacological 
end points. The system enables the generation of focused li braries 
covering a wide range of chemica l diversity patterns around specific 
conditions, mechanisms of action or selected chemical scaffo lds. 
The screening of generated vi rtual compounds has demonstrated 
a strong correlation between predicted and real mechanisms of ac-
tion, along with a convenient ADMET profile. 
The corresponding synthesis and experimenta l validation has led 
Vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine ki- to a series of small-molecule BDNF modulators which have been 
nase is involved in cancer and in angiogenesisY I Herein, we report the selected for further pha rmacological evaluation. 
synthesis of novel1-aryl-3-[2-, 3- or 4-{thieno[3,2-b ]pyridin-7-ylthio) 
phenyl]ureas as VEGFR2 inhibitors by promoting the regioselective 
attack of the thiol group of the 4-aminothiophenol in the chlorine 
nucleophilic displacement on 7-chlorothieno[3,2-b]pyridine 1, ob-
taining the aminated compounds Za- c. These were reacted with 
arylisocyanates to give the corresponding 1,3-diarylureas 3a-c, 4a-c 
and Sa-c (see scheme). 
1-Aryl-3-[3-(thi eno[3, 2 -b] pyridin-7-ylthio )phenyl]ureas 4a-c with 
the arylurea in the meta position relative to the thioether showed 
the lowest IC50 values (0.4-0.9 ~M) in enzymatic assays using VEGFR2 
tyrosine kinase domain, and the binding mode for these compounds 
was predicted by docking simulations. 
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